Clinical trial
Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without…
NCT00367471 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00367471 |
|---|---|
| Title | Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer. |
| Official title | A Phase I, Dose Escalation Study to Assess the Safety and Tolerability of Lapatinib in Combination With Carboplatin, Paclitaxel, With and Without Trastuzumab in Subjects With Metastatic Breast Cancer |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms, Breast |
| Intervention type | Drug |
| Interventions | lapatinib, carboplatin, trastuzumab, paclitaxel |
| Enrollment | 31 |
| Start date | Dec 7, 2006 |
| Primary completion | Dec 22, 2010 |
| Completion | Sep 12, 2019 |
| First posted | Aug 23, 2006 |
| Last update posted | Sep 9, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: